6月10日，科伦博泰生物盘中上涨3.25%，报400.0港元，成交额1.38亿港元。消息面上，野村近日维持公司"买入"评级并将目标价上调至544.42港元，中信建投亦维持"买入"评级，核心逻辑均指向公司芦康沙妥珠单抗III期OptiTROP-Lung05研究数据，联合用药组PFS风险比达0.35，系全球首个在PD-L1阳性非小细胞肺癌中显示PFS改善的ADC药物，成果已同步发表于《柳叶刀》。此外，公司此前发布的回购不超过已发行H股10%的计划亦对股价形成支撑，尽管董事长近期连续减持仍对市场信心有所压制，但重磅临床数据与机构看多共振推动股价回升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.